Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05815173 · ClinicalTrials.gov registry record · Phase 1
Ladarixin With Sotorasib in Advanced NSCLC
A Phase 1 study of Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT05815173: Recruiting Phase 1 study of Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation, sponsored by NYU Langone Health.
NCT05815173 is a Phase 1 study of Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 6 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05815173, a Phase 1 study of Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC).
Primary Outcome
DLTs are defined as side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
Conditions Studied
Interventions
- DRUG Sotorasib
- DRUG Ladarixin
Study Locations (6)
New York
- NYU Langone Health - Garden City
- NYU Langone Health - Mineola
- NYU Langone Health - New Hyde Park
- NYU Langone Health - New York
- NYU Langone Health - New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT05815173 shows while recruiting
NCT05815173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation appearing as the primary indexed condition, and to 2 interventions - of which Sotorasib is the first listed.
NCT05815173 lists 6 locations in 1 state (New York).
Frequently Asked Questions
What is clinical trial NCT05815173 about?
NCT05815173 is a clinical study titled "Ladarixin With Sotorasib in Advanced NSCLC". This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC).
What is the current status of trial NCT05815173?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-08-01. Estimated completion is 2027-08.
What conditions does trial NCT05815173 study?
This clinical trial studies the following conditions: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation.
What interventions are being tested in trial NCT05815173?
The interventions under investigation include: Sotorasib (DRUG), Ladarixin (DRUG).
Who is sponsoring clinical trial NCT05815173?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05815173 being conducted?
This trial has 6 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05815173's enrollment target sits among peer trials
40 1131st of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI